Evaluation of the efficacy, safety and injection interval of intravitreal injection of aflibercept for age-related macular degeneration

Evaluation of the efficacy, safety and injection interval of intravitreal injection of aflibercept for age-related macular degeneration - Trimonthly intravitreal injection of aflibercept for age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019028

Enrollment

Registered

2015-09-15

Start date

2015-09-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration

Interventions

Duration:12 months Quantity: aflibercept 2.0mg/0.05mL Trimonthly injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients of Shiga University of Medical Science Hospital with age-related macular degeneration Patients underwent a full ocular examination, including fluorescein angiography

Exclusion criteria

Exclusion criteria: severe renal disease unstable angina malignant arrhythmia history of brain infarction history of cerebral hemorrhage severe hypertension

Design outcomes

Primary

Measure	Time frame
change in best-corrected visual acuity (BCVA) from baseline to every visits change in central retinal thickness from baseline to every visits	—

Secondary

Measure	Time frame
rate of adverse events change on fluorescein angiography	—

Countries

Japan

Contacts

Public ContactYuka Ito

Shiga University of Medical Science Department of Ophthalmology

yukaito@belle.shiga-med.ac.jp077-548-2276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026